Citations

Clear

171 citation(s) found for "Lipton, RB".

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
Diener, HC, Dodick, DW, Aurora, SK, Turkel, CC, DeGryse, RE, Lipton, RB, Silberstein, SD, Brin, MF

Mayo Clinic

Cephalalgia | March 17, 2010 | Volume: 30 | Issue: 7 | Pages: 804-814

10.1177/0333102410364677 | PMID 20647171 Get It

Objectives: This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic migraine. Methods: PREEMPT 2 was a phase 3 study, with a 24-week, double-blind, placebo-controlled phase, followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections of onabotulinumtoxinA (155U–195U; n = 347) or placebo ( n = 358) every 12 weeks for two cycles. The primary efficacy endpoint was mean change in headache days per 28 days from baseline to weeks 21–24 post-treatment. Results: OnabotulinumtoxinA was statistically significantly superior to placebo for the primary endpoint, frequency of headache days per 28 days relative to baseline (−9.0 onabotulinumtoxinA/−6.7 placebo, p < .001). OnabotulinumtoxinA was significantly favoured in all secondary endpoint comparisons. OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few patients (3.5% onabotulinumtoxinA/1.4% placebo) discontinued due to adverse events. Conclusions: The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine. Repeated onabotulinumtoxinA treatments were safe and well tolerated.
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
Aurora, SK, Dodick, DW, Turkel, CC, DeGryse, RE, Silberstein, SD, Lipton, RB, Diener, HC, Brin, MF, Dashtipour, Khashayar

Mayo Clinic

Cephalalgia | March 17, 2010 | Volume: 30 | Issue: 7 | Pages: 793-803

10.1177/0333102410364676 | PMID 20647170 Get It

Objectives: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Methods: The Phase III REsearch Evaluating Migraine Prophylaxis Therapy 1 (PREEMPT 1) is a phase 3 study, with a 24-week, double-blind, parallel-group, placebo-controlled phase followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections every 12 weeks of onabotulinumtoxinA (155 U–195 U; n = 341) or placebo ( n = 338) (two cycles). The primary endpoint was mean change from baseline in headache episode frequency at week 24. Results: No significant between-group difference for onabotulinumtoxinA versus placebo was observed for the primary endpoint, headache episodes (−5.2 vs. −5.3; p = 0.344). Large within-group decreases from baseline were observed for all efficacy variables. Significant between-group differences for onabotulinumtoxinA were observed for the secondary endpoints, headache days ( p = .006) and migraine days ( p = 0.002). OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few subjects discontinued due to adverse events. Conclusions: There was no between-group difference for the primary endpoint, headache episodes. However, significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.
P4‐132: Progranulin gene polymorphism (GRN rs5848) that is associated with FTLD‐U is increased in African‐Americans and shows a tendency to correlate with cognitive performance in subjects enrolled in the Einstein Aging Study
Rademakers, Rosa , Surtees, Rebecca, Baker, Matt , Katz, Mindy J. , Sanders, Amy E. , Wang, Cuiling , Derby, Carol A. , Dickson, Dennis W. , Lipton, Richard B.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2009.04.800 Get It

P4‐168: Antemortem IL‐6 levels associated with vascular pathology but not Alzheimer pathology in cases from the Einstein Aging Study
Sanders, Amy , Derby, Carol A. , Lipton, Richard B. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_16 | Pages: No page available

10.1016/j.jalz.2009.04.735 Get It

Consistency of Response to Sumatriptan/Naproxen Sodium in a Placebo-Controlled, Crossover Study
Lipton, RB, Dodick, DW, Ju, Adelman, Kaniecki, R. G., Lener, SE, White, J A, Nelsen, AC

Mayo Clinic

Cephalalgia | February 12, 2009 | Volume: 29 | Issue: 8 | Pages: 826-836

10.1111/j.1468-2982.2008.01806.x | PMID 19220307 Get It

Two identical randomized, placebo-controlled, crossover studies were conducted to evaluate consistency of response to sumatriptan/naproxen sodium 85/500 mg (S/NS) over four attacks in adults with migraine. Patients were instructed to treat within 1 h of pain onset while pain was mild. Co-primary end-points were pain-free response at 2 h (2hPF) and 24-h sustained pain-free response (24hSPF) calculated as percentages of all attacks. In Study 1, 570 patients treated 1693 attacks with S/NS and 424 with placebo. In Study 2, 565 patients treated 1678 attacks with S/NS and 422 with placebo. Compared with placebo, S/NS conferred higher 2hPF rates (Study 1: S/NS 52%, placebo 25%; Study 2: S/NS 50%, placebo 20%; both P < 0.001) and higher 24hSPF rates (Study 1: S/NS 37%, placebo 17%; Study 2: S/NS 34%, placebo 12%; both P < 0.001). 2hPF was reported in at least two of the first three S/NS-treated attacks in 55.0% of patients in Study 1 and 52.1% of patients in Study 2. 24hSPF was reported in at least two of the first three S/NS-treated attacks in 35.7% of patients in Study 1 and 32.6% of patients in Study 2. The incidences of any adverse event and of specific adverse events were low and generally similar between S/NS and placebo.
P3‐027: Hippocampal sclerosis and TDP‐43 immunoreactivity: A clinicopathological study
Zwerling, Jessica , Zimmerman, Molly E. , Sanders, Amy , Verghese, Joe , Lipton, Richard B. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_16 | Pages: No page available

10.1016/j.jalz.2008.05.1590 Get It

P3‐175: Cognitive trajectories in hippocampal sclerosis, Alzheimer's disease, and vascular dementia: A pathology series from the Einstein Aging Study (EAS) brain bank
Sanders, Amy E. , Katz, Mindy J. , Wang, Cuiling , Verghese, Joe , Zimmerman, Molly E. , Dickson, Dennis W. , Derby, Carol A. , Lipton, Richard B.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2008.05.1741 Get It

Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults
Silberstein, Stephen D., Tfelt‐Hansen, Peer , Dodick, DW, Limmroth, Volker , Lipton, RB, Wang, S. J., Lipton, RB, Pascual, Julio

Mayo Clinic

Cephalalgia | February 20, 2008 | Volume: 28 | Issue: 5 | Pages: 484-495

10.1111/j.1468-2982.2008.01555.x | PMID 18294250 Get It

In 1991 the Clinical Trials Subcommittee of the International Headache Society (IHS) developed and published its first edition of the Guidelines on controlled trials of drugs in episodic migraine because only quality trials can form the basis for international collaboration on drug therapy, and these Guidelines would ‘improve the quality of controlled clinical trials in migraine’. With the current trend for large multinational trials, there is a need for increased awareness of methodological issues in clinical trials of drugs and other treatments for chronic migraine. These Guidelines are intended to assist in the design of well-controlled clinical trials of chronic migraine in adults, and do not apply to studies in children or adolescents.
Identification of Negative Predictors of Pain-Free Response to Triptans: Analysis of the Eletriptan Database
Diener, HC, Dodick, DW, Goadsby, Peter J. , Lipton, RB, Almas, Mary , Parsons, Bruce , Goadsby, Peter J

Mayo Clinic

Cephalalgia | October 18, 2007 | Volume: 28 | Issue: 1 | Pages: 35-40

10.1111/j.1468-2982.2007.01457.x | PMID 17941878 Get It

Thirty to forty percent of migraineurs do not respond to any given triptan treatment. We identified clinical variables that significantly predict therapeutic non-response and evaluated the efficacy of eletriptan (20, 40 and 80 mg) and sumatriptan (100 mg) vs. placebo in a subgroup of patients with all predictor variables. First-attack data were pooled from 10 randomized, double-blind, placebo-controlled migraine trials ( n = 8473). Multivariate regression analyses identified three significant baseline predictors of failure to achieve 2-h pain-free response: severe headache pain, presence of photophobia/phonophobia and presence of nausea. Time of dosing following headache onset did not influence 2-h pain-free response. Among patients with all three risk factors ( n = 2010; 24± of total sample), 2-h pain-free response was significantly higher in patients receiving all three doses of eletriptan or sumatriptan vs. placebo (all P< 0.01). Thus, eletriptan and sumatriptan are efficacious in difficult-to-treat patients at high risk for non-response to triptans.
Treatment-Emergent CNS Symptoms Following Triptan Therapy are Part of The Attack
Goadsby, PJ, Dodick, DW, Almas, Mary , Diener, H-C, Tfelt‐Hansen, Peer , Lipton, RB, Parsons, Bruce , Lipton, RB

Mayo Clinic

Cephalalgia | February 7, 2007 | Volume: 27 | Issue: 3 | Pages: 254-262

10.1111/j.1468-2982.2007.01278.x | PMID 17381558 Get It

If treatment-emergent central nervous system (CNS) symptoms following triptan therapy represent direct pharmacological effects of the drug, they should occur independent of response to active drug. However, if they represent unmasking of neurological symptoms of the migraine attack after pain is relieved, they should be more common in responders both to active drug and to placebo. To explore this issue, we evaluated the relationship between the CNS adverse events and treatment response following triptan or placebo treatment. We used pooled data from seven double-blind, placebo-controlled trials involving eletriptan 20 mg (E20, n = 402), eletriptan 40 mg (E40, n = 1870), eletriptan 80 mg (E80, n = 1393), sumatriptan 100 mg (S100, n = 275) and placebo (Pbo, n = 1024). Somnolence was more prevalent among 2 h headache responders than non-responders for all treatments, including E80 (8.8% vs. 5.0%; P < 0.05), E40 (6.4% vs. 5.0%; NS), E20 (4.0% vs. 2.0%; NS), S100 (4.7% vs. 3.2%; NS) and Pbo (7.6% vs. 3.0%; P < 0.05). Similarly, the incidence of asthenia was higher among patients who responded to treatment compared with those who did not respond to E80 (15.2% vs. 7.8%; P < 0.05), E40 (6.5% vs. 3.6%; P < 0.05), E20 (6.5% vs. 1.0%; P < 0.05), S100 (10.1% vs. 4.7%; NS) and Pbo (4.4% vs. 2.7%; NS). The generally higher rates of somnolence and asthenia in patients who respond to treatment suggests that these treatment-emergent neurological symptoms may represent the unmasking of CNS symptoms associated with the natural resolution of a migraine attack, rather than simply representing drug-related side-effects. The rate of somnolence in placebo responders is comparable to that in responders to E40 and E80, indicating that somnolence is related, at least in some important part, to headache relief and not treatment.